Possibility of active targeting to tumor tissues with liposomes

Advanced Drug Delivery Reviews

Volumn 40, Issue 1-2, 1999, Pages 89-102

  Maruyama, Kazuo ^a   Ishida, Osamu ^a   Takizawa, Tomoko ^a   Moribe, Kunikazu ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

Active targeting; Extravasation; Immunoliposome; Polyethyleneglycol; Transferrin

Indexed keywords

CELLS; ONCOLOGY; POLYETHYLENE GLYCOLS;

IMMUNOLIPOSOMES;

CONTROLLED DRUG DELIVERY;

AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; DOXORUBICIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; MACROGOL DERIVATIVE; PLASMID DNA; TRANSFERRIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; ENDOCYTOSIS; EXTRAVASATION; INTERNALIZATION; KAPOSI SARCOMA; LUNG ASPERGILLOSIS; NEUROBLASTOMA; NONHUMAN; PASSIVE TRANSPORT; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; SOLID TUMOR;

EID: 0032824375     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00042-3     Document Type: Article

References (38)

1. Ehrlich P.A. General review of the recent work in immunity. Himmelweit F. Immunology and Cancer Research. 1956;Pergamon Press, London.
2. Poste G., Kirsh R. Site-specific (targeted) drug delivery in cancer therapy. Biotechnology. 1:1983;869-878.
3. Gupta P.K. Drug targeting in cancer chemotherapy: a clinical perspective. J. Pharm. Sci. 79:1990;949-962.
4. Rowlinson-Busza G., Epenetos A.A. Targeted delivery of biologic and other antineoplastic agents. Curr. Opin. Oncol. 4:1992;1142-1148.
5. Cummings J., Smyth J.F. Cytotoxic drug delivery. Florence A.T., Salole E.G. Topics in Pharmacy. III:1993;27-53 Butterworth-Heinemann, Oxford.
6. Lasic D.D., Papahadjopoulos D. Liposomes revisited. Science. 267:1995;1275-1276.
7. Leserman L., Machy P. Ligand targeting of liposomes. Ostro M.J. Liposomes. From Biophysics to Therapeutics. 1987;157-194 Marcell Dekker, New York.
8. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
9. Peeters P.A.M., Storm G., Crommelin D.J.A. Immunoliposomes in vivo: state of the art. Adv. Drug Deliv. Rev. 1:1987;249-266.
10. Aragnol D., Leserman L.D. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc. Natl. Acad. Sci. USA. 83:1986;2699-2703.
11. Derksen J.T.P., Marselt H.W.M., Scherphof G.L. Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages. Biochim. Biophys. Acta. 971:1988;127-136.
12. Maruyama K., Holmberg E., Kennel S.J., Klibanov A., Torchilin V.P., Huang L. Characterization of in vivo immunoliposome targeting to pulmonary endothelium. J. Pharm. Sci. 79:1990;978-984.
13. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6:1987;559.
14. Dvorak H.F., Nagy J.A., Dvorak J.T., Dvorak A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133:1988;95-109.
15. Jain R.K., Gerlowski L.E. Extravascular transport in normal and tumor tissue. Crit. Rev. Oncol. Hematol. 5:1986;115-170.
16. Maeda H. The tumor blood vessel as an ideal target for macromolecular anticancer agents. J. Control. Release. 19:1992;315-324.
17. Maeda H., Seymour L.W., Miyamoto Y. Conjugation of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem. 3:1992;351-362.
18. Young R.C., Ozols R.E., Mayers C.E. The anthracycline antineoplastic drugs. New Engl. J. Med. 305:1981;139-153.
19. Lasic D. Application of liposomes in pharmacology and medicine. Lasic D. Liposomes From Physics to Applications. 1993;262-471 Elsevier, Amsterdam.
20. Hwang K.J. Liposome pharmacokinetics. Ostro M.J. Liposome from Biophysics to Therapeutics. 1987;109-156 Marcel Dekker Inc, New York.
21. Senior J.H. Fate and behavior in vivo: a review of controlling factors. Crit. Rev. Drug Carrier Syst. 3:1987;123-139.
22. Allen T.M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 223:1987;42-46.
23. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:1990;235-237.
24. Maruyama K., Yuda T., Okamoto A., Kojima S., Suginaka A., Iwatsuru M. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim. Biophys. Acta. 1128:1992;44-49.
25. Allen T.M., Hansen C., Martin F.L., Redemann C., Young A.Y. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta. 1066:1991;29-36.
26. Yuan F., Leuning M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54:1994;3352-3356.
27. Unezaki S., Maruyama K., Hosoda J., Nagae I., Koyanagi Y., Nakata M., Ishida O., Iwatsuru M., Tsuchiya S. Direct measurement of extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int. J. Pharm. 144:1996;11-17.
28. Huang S.K., Lee K.D., Hong K., Friend D.S., Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52:1992;5135-5143.
29. Maruyama K., Takizawa T., Yuda T., Kennel S.J., Huang L., Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic polyethyleneglycols conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta. 1234:1995;74-80.
30. Maruyama K., Kennel S.J., Huang L. Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc. Natl. Acad. Sci. USA. 87:1990;5744-5748.
31. Kennel S.J., Lankfold T., Hughes B., Hotchkiss J.A. Quantitation of a murine lung endothelial cell protein, P112, with a double monoclonal antibody assay. Laboratory Investigation. 59:1988;692-701.
32. Otsubo T., Maruyama K., Maesaki S., Miyazaki Y., Tanaka E., Takizawa T., Moribe K., Tomono K., Tashiro T., Kohno S. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice. Antimicro. Agents Chemother. 42:1998;40-44.
33. Uyama I., Kumai K., Yasuda T., Tagawa T., Ishibiki K., Kitajima M., Tadakuma T. Improvement of therapeutic effect by using Fab' fragment in the treatment of carcinoembryonic antigen-positive human solid tumors with adriamycin-entrapped immunoliposomes. Jpn. J. Cancer Res. 85:1994;434-440.
34. Maruyama K., Takahashi N., Tagawa T., Nagaike K., Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into target solid tumors in vivo. FEBS Lett. 413:1997;177-180.
35. Gatter K., Brown G., Trowbridge I.S., Woolston R., Mason D.Y. J. Clin. Pathol. 36:1987;539-545.
36. Motov K.E., Simister N.E. Transcytosis. Cell. 43:1985;389-390.
37. Unezaki S., Maruyama K., Takahashi N., Koyama M., Yuda T., Suginaka A., Iwatsuru M. Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethyleneglycol in combination with local hyperthermia. Pharm. Res. 11:1994;1180-1185.
38. Katayama K., Takizawa T., Maruyama K., Iwatsuru M., Kono K. Fusogenic immunoliposomes modified by pH-sensitive PEG derivatives. Prog. Drug Deliv. Syst. 7:1998;29-38.